title: Outcome Measures in Myasthenia Gravis: Incorporation Into Clinical Practice.
abstract: The development of validated assessment tools for evaluating disease status and response to interventions in patients with myasthenia gravis (MG) has been driven by clinical studies of emerging MG therapies. However, only a small proportion of MG-focused neurology practices have adopted these assessment tools for routine clinical use. This article reviews the suitability of 5 assessment instruments for incorporation into clinical practice, which should be driven by their ability to contribute to improved patient outcomes, and to be implemented within practice personnel and resource constraints. It is recommended that assessments based on both physician-evaluated and patient-reported outcomes be selected, to adequately evaluate both point-in-time symptom load and functional impact of MG symptoms over time. Provider resource allocation and reimbursement issues may be the most significant roadblocks to successful ongoing use of these tools; to that end, the addition of regular assessments to MG standards of care is recommended.
authors.affiliation: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.
authors.forename: Srikanth
authors.initials: S
authors.lastname: Muppidi
mesh_terms: D000203:Activities of Daily Living; D001323:Autoantibodies / Q000097:blood*; D006801:Humans; D009157:Myasthenia Gravis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D063189:Symptom Assessment
chemical_list: D001323:Autoantibodies